Edinburgh-based biotech startup Concinnity, which develops AI-driven RNA control systems for gene and cell therapies, has raised £3 million in a seed round led by Eos Advisory, with additional participation from Scottish Enterprise, Old College Capital, and Maven Capital Partners.
- Founded in 2021 by Jessica Birt and Dr. Matthew Dale, Concinnity is a spinout from the University of Edinburgh. The company is developing an AI-driven RNA design platform to create gene control systems for gene and cell therapies, enabling precise control over therapeutic activity.
- Concinnity focuses on improving the safety of gene therapies by designing RNA-based control systems that can dynamically adjust based on patient conditions, such as disease state or tissue type, and allow for clinical control after administration.
Details of the deal
- The seed round was led by Eos Advisory, a firm that invests in and commercializes science and technology, focusing on improving lives from the seed stage to the global scale.
- Glasgow-based Scottish Enterprise, Old College Capital, the University of Edinburgh’s venture investment fund, and Maven Capital Partners, also joined the round.
- The fresh capital will enable Concinnity to spin out from the University of Edinburgh, establish operations in Scotland’s life science hub, and fund new programs in cell and gene therapy, while continuing to develop its control systems.
“This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology," co-founder and CEO of Concinnity, Jessica Birt, stated.
